Cytosorbents Co. (NASDAQ:CTSO – Get Rating) – SVB Leerink dropped their FY2025 earnings per share (EPS) estimates for Cytosorbents in a note issued to investors on Tuesday, May 3rd. SVB Leerink analyst D. Antalffy now forecasts that the medical research company will post earnings per share of $0.16 for the year, down from their previous forecast of $0.21.
Cytosorbents (NASDAQ:CTSO – Get Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.06). Cytosorbents had a negative return on equity of 42.43% and a negative net margin of 71.16%. During the same period in the prior year, the company posted ($0.10) earnings per share.
Shares of NASDAQ CTSO traded down $0.09 during trading on Friday, hitting $1.88. The company had a trading volume of 544 shares, compared to its average volume of 226,846. The stock has a 50 day simple moving average of $3.01 and a 200 day simple moving average of $4.05. Cytosorbents has a 12 month low of $1.80 and a 12 month high of $9.80. The firm has a market capitalization of $81.89 million, a P/E ratio of -2.90 and a beta of 0.48.
Several institutional investors have recently made changes to their positions in CTSO. Morgan Stanley boosted its holdings in shares of Cytosorbents by 17.5% in the 2nd quarter. Morgan Stanley now owns 236,123 shares of the medical research company’s stock worth $1,783,000 after purchasing an additional 35,166 shares during the period. Millennium Management LLC purchased a new position in shares of Cytosorbents in the 2nd quarter worth approximately $394,000. SG Americas Securities LLC purchased a new position in shares of Cytosorbents in the 3rd quarter worth approximately $114,000. M&G Investment Management Ltd. boosted its holdings in shares of Cytosorbents by 37.1% in the 3rd quarter. M&G Investment Management Ltd. now owns 205,801 shares of the medical research company’s stock worth $1,646,000 after purchasing an additional 55,657 shares during the period. Finally, Barclays PLC lifted its stake in shares of Cytosorbents by 188.7% during the 3rd quarter. Barclays PLC now owns 17,166 shares of the medical research company’s stock worth $140,000 after acquiring an additional 11,221 shares during the last quarter. Hedge funds and other institutional investors own 40.98% of the company’s stock.
Cytosorbents Company Profile (Get Rating)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.
- Get a free copy of the StockNews.com research report on Cytosorbents (CTSO)
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.